Novel bladder preservation therapy for locally invasive bladder cancer: Combined therapy using balloon-occluded arterial infusion of anticancer agent and hemodialysis with concurrent radiation

International Journal of Oncology

Volumn 37, Issue 4, 2010, Pages 773-785

  Azuma, Haruhito ^a   Inamoto, Teruo ^a   Ibuki, Naokazu ^a   Ubai, Takanobu ^a   Kotake, Yatsugu ^a   Takahara, Kiyoshi ^a   Kiyama, Satoshi ^a   Nomi, Hayahito ^a   Uehara, Hiroshi ^a   Komura, Kazumasa ^a   Yamamoto, Kazuhiro ^a   Narumi, Yoshihumi ^a   Katsuoka, Yoji ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Balloon occluded arterial infusion; Hemodialysis; Invasive bladder cancer; OMC regimen

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE; CISPLATIN; GEMCITABINE;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BALLOON OCCLUDED ARTERIAL INFUSION; BALLOON OCCLUSION; BLADDER CANCER; CANCER GROWTH; CANCER INVASION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CONSTIPATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYSTECTOMY; DIARRHEA; DISEASE COURSE; FEMALE; FOLLOW UP; GENITAL SYSTEM DISEASE; GRANULOCYTOPENIA; HEMODIALYSIS; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUROPATHY; ORGAN PRESERVATION; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT DISEASE; RISK FACTOR; SALVAGE THERAPY; SIDE EFFECT; TREATMENT FAILURE; TREATMENT RESPONSE; URINARY DYSFUNCTION; VOMITING;

EID: 77956499362     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000727     Document Type: Article

References (26)

1. Stenzl A, Cowan NC, De Santis M, et al: Guidelines on bladder cancer muscle-invasive and metastatic. Eur Assoc Urol 3: 1-59, 2008.
2. Hong S, Kwak C, Jeon H, Lee E and Lee S: Do vascular, lymphatic, and perineural invasion have prognostic implications for bladder cancer after radical cystectomy? Urology 65: 697-702, 2005.
3. Leissner J, Koeppen C and Wolf H: Prognostic significance of vascular and perineural invasion in urothelial bladder cancer treated with radical cystectomy. J Urol 169: 955-960, 2003.
4. Patton S, Hall M and Ozen H: Bladder cancer. Curr Opin Oncol 14: 265-272, 2002.
5. Shelley MD, Barber J and Wilt T: Surgery versus radiotherapy for invasive bladder cancer. Cochrane Database Syst Rev: CD002079, 2002.
6. Stein JP, Lieskovsky G, Cote R, et al: Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19: 666-675, 2001.
7. Dalbagni G, Genega E, Hashibe M, et al: Cystectomy for bladder cancer: a contemporary series. J Urol 165: 1111-1116, 2001. (Pubitemid 32210214)
8. Frazier H, Robertson J, Dodge R and Paulson D: The value of pathologic factors in predicting cancer-specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate. Cancer 71: 3993-4001, 1993.
9. Shipley WU, Prout GRJ, Einstein AB, et al: Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery. JAMA 258: 931-935, 1987.
10. Tester W, Caplan R, Heaney J, et al: Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol 14: 119-126, 1996.
11. Shipley WU, Winter KA, Kaufman DS, et al: Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol 16: 3576-3583, 1998.
12. Kaufman DS, Winter KA, Shipley WU, et al: The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with con-current cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. Oncologist 5: 471-476, 2000.
13. Hagan MP, Winter KA, Kaufman DS, et al: RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys 57: 665-672, 2003.
14. Weiss C, Engehausen DG, Krause FS, et al: Radiochemotherapy with cisplatin and 5-fluorouracil after transurethral surgery in patients with bladder cancer. Int J Radiat Oncol Biol Phys 68: 1072-1080, 2007. (Pubitemid 47048579)
15. Gogna NK, Matthews JH, Turner SL, et al: Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: a report of two sequential phase II studies from the Trans Tasman Radiation Oncology Group. Radiother Oncol 81: 9-17, 2006.
16. Greene FL, Page DL and Fleming ID: AJCC Cancer Staging manual. 6th edition. Springer Verlag, New York, pp335-340, 2002.
17. Ficcara V, Dalpiaz O, Alrabi N, Novara G, Galfano A and Artibani W: Correlation between clinical and pathological staging in a series of radical cystectomies for bladder carcinoma. BJU Int 95: 786-790, 2005.
18. Collins JM: Pharmacokinetic rationale for intraarterial therapy. In: Cancer Chemotherapy, Challenges for the Future. Vol. 4. Kimura K (ed). Excepta Medica, Amsterdam, 1989.
19. Mitsuzane K, Kawabata M, Terada M, Nomura S, Sato M and Yamada R: Balloon-occluded arterial infusion as chemotherapy in bladder cancer-long-term results. Jpn J Cancer Chemother 17: 1701-1704, 1990.
20. Cvitkovic E, Spaulding J, Bethune V, Martin J and Whitmore WF: Improvement of cis-dichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model. Cancer 39: 1357-1361, 1977. (Pubitemid 8108285)
21. Douple EB and Richmond RC: A review of platinum complex biochemistry suggests a rationale for combined platinum-radiotherapy. Int J Radiat Oncol Biol Phys 8: 1335-1339, 1979.
22. Abbott DW, Freeman ML and Holt JT: Double-strand break repair deficiency and radiation sensitivity in BRCA2 mutant cancer cells. J Natl Cancer Inst 90: 978-985, 1998.
23. Brown JM and Wouters BG: Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res 59: 1391-1399, 1999.
24. Chadwick KH, Leenhouts HP, Szumiel I and Nias AH: An analysis of the interaction of a platinum complex and radiation with CHO cells using the molecular theory of cell survival. Int J Radiat Biol Relat Stud Phys Chem Med 6: 511-524, 1976.
25. Belt RJ, Himmelstein KJ, Patton TF, Bannister SJ, Sternson LA and Repta AJ: Pharmacokinetics of non-protein-bound platinum species following administration of cis-dichlorodiammine-platinum( II). Cancer Treat Rep 63: 1515-1521, 1979.
26. Himmelstein KJ, Patton TF, Belt RJ, Taylor S, Repta AJ and Sternson LA: Clinical kinetics on intact cisplatin and some related species. Clin Pharmacol Ther 29: 658-664, 1981.